医学
腰椎管狭窄症
腰椎
间歇性跛行
椎管狭窄
神经源性跛行
狭窄
外科
麻醉
跛行
放射科
血管疾病
动脉疾病
作者
Austin Marcolina,Kevin Vu,Thiru M. Annaswamy
出处
期刊:American Journal of Physical Medicine & Rehabilitation
[Ovid Technologies (Wolters Kluwer)]
日期:2020-10-16
卷期号:100 (3): 297-302
被引量:9
标识
DOI:10.1097/phm.0000000000001620
摘要
Abstract Lumbar spinal stenosis is one of the most commonly diagnosed spinal disorders worldwide and remains a major cause for surgery in older adults. Lumbar spinal stenosis is clinically defined as a progressive degenerative disorder with low back pain and associated neurogenic intermittent claudication. Conservative and surgical management of lumbar spinal stenosis has been shown to be minimally effective on its symptoms. A treatment option that has not been investigated in the United States is the utilization of prostaglandin E 1 analogs, which have been used primarily in Japan for the treatment of lumbar spinal stenosis since the 1980s. The vasodilatory and antiplatelet aggregation effects of prostaglandin E 1 presumably improve symptoms of lumbar spinal stenosis by increasing blood flow to the spinal nerve roots. This brief report examines the potential vascular pathology of lumbar spinal stenosis, reviews evidence on the use of prostaglandin E 1 analog limaprost in Japan for lumbar spinal stenosis, and briefly discusses misoprostol as a possible alternative in the United States. The studies summarized in this report suggest that prostaglandin E 1 analogs may provide benefit as a conservative treatment option for patients with lumbar spinal stenosis. However, higher-quality studies conducted in the United States and comparison with other currently used conservative treatments are required before it can be recommended for routine clinical use.
科研通智能强力驱动
Strongly Powered by AbleSci AI